Search for more clinical trials
DNA Analysis of Blood and Tissue From Patients With Lung Cancer
Conditions
Lung Cancer
Conditions: official terms
Lung Neoplasms
Conditions: Keywords
non-small cell lung cancer, small cell lung cancer, pulmonary carcinoid tumor
Study Type
Observational
Study Phase
N/A
Study Design
N/A
Intervention
Name: polymerase chain reaction
Type: Genetic
Name: polymorphism analysis
Type: Genetic
Name: diagnostic laboratory biomarker analysis
Type: Other
Overall Status
Recruiting
Summary
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help the study of cancer in the future.
PURPOSE: This clinical trial is analyzing the DNA in blood and tissue samples from patients with lung cancer.
PURPOSE: This clinical trial is analyzing the DNA in blood and tissue samples from patients with lung cancer.
Detailed Description
OBJECTIVES:
- Assess the role of genetic polymorphisms in lung-cancer risk in patients with lung cancer.
- Assess the role of germline polymorphisms in DNA repair genes, p53 pathway genes, and a matrix metalloproteinase gene (tumor invasion factor) in lung-cancer risk, after adjusting for potential confounders.
- Assess the roles of gender and age in the genetic susceptibility of lung cancer.
- Assess the role of genetic polymorphisms in modifying the diet-lung cancer risk association (gene-diet and exploratory gene-gender-diet and gene-gene-diet interactions).
- Assess the role of polymorphisms on the risk of developing specific histologic subtypes of lung cancer in case-only analyses.
- Determine whether continued exposures to mainstream and/or second-hand tobacco smoking is associated with poorer clinical prognosis in patients treated for lung cancer.
OUTLINE: This is a case-control study.
Blood samples are collected from patients and controls. Samples are analyzed by polymerase chain reaction for gene polymorphisms. Genes to be studied include GSTP1, GSTM1, GSTT1, ERCC2, XRCC1, EPHX, NAT-2, p53 gene, CYP1A1, NQO1, MnSOD, and GPX1. Tissue samples collected from patients undergoing surgery and blood samples are archived for future studies.
Patients and controls complete questionnaires about diet, medical history, and occupational/environmental history.
PROJECTED ACCRUAL: A total of 3,400 patients and 3,400 controls will be accrued for this study.
- Assess the role of genetic polymorphisms in lung-cancer risk in patients with lung cancer.
- Assess the role of germline polymorphisms in DNA repair genes, p53 pathway genes, and a matrix metalloproteinase gene (tumor invasion factor) in lung-cancer risk, after adjusting for potential confounders.
- Assess the roles of gender and age in the genetic susceptibility of lung cancer.
- Assess the role of genetic polymorphisms in modifying the diet-lung cancer risk association (gene-diet and exploratory gene-gender-diet and gene-gene-diet interactions).
- Assess the role of polymorphisms on the risk of developing specific histologic subtypes of lung cancer in case-only analyses.
- Determine whether continued exposures to mainstream and/or second-hand tobacco smoking is associated with poorer clinical prognosis in patients treated for lung cancer.
OUTLINE: This is a case-control study.
Blood samples are collected from patients and controls. Samples are analyzed by polymerase chain reaction for gene polymorphisms. Genes to be studied include GSTP1, GSTM1, GSTT1, ERCC2, XRCC1, EPHX, NAT-2, p53 gene, CYP1A1, NQO1, MnSOD, and GPX1. Tissue samples collected from patients undergoing surgery and blood samples are archived for future studies.
Patients and controls complete questionnaires about diet, medical history, and occupational/environmental history.
PROJECTED ACCRUAL: A total of 3,400 patients and 3,400 controls will be accrued for this study.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: N/A
Gender: Both
Criteria: DISEASE CHARACTERISTICS:
- Patient:
- Newly diagnosed lung cancer
- Patient at Massachusetts General Hospital (MGH) or Boston Medical Center Cancer Center
- Control:
- Nonblood-related friend or spouse of the patient
- No specific matching characteristics
- Friend or spouse of other hospital patients
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
- Patient:
- Newly diagnosed lung cancer
- Patient at Massachusetts General Hospital (MGH) or Boston Medical Center Cancer Center
- Control:
- Nonblood-related friend or spouse of the patient
- No specific matching characteristics
- Friend or spouse of other hospital patients
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Locations
Harvard School of Public Health
Boston, Massachusetts, United States
Massachusetts General Hospital
Status: Recruiting
Contact: David C. Christiani, MD - 617-726-9274
Boston, Massachusetts, United States
Status: Recruiting
Contact: Clinical Trials Office - Massachusetts General Hospital - 877-726-5130
Start Date
September 2005
Sponsors
Massachusetts General Hospital
Source
National Cancer Institute (NCI)
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page